WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

June 02, 2005 11:52 ET

WEX Pharmaceuticals Inc.: Protocol Amendment Approved by Health Canada

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 2, 2005) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that it has received a No Objection Letter (NOL) from Health Canada to amend the Phase IIb/III clinical trial protocol for Tectin™ in moderate to severe inadequately controlled cancer-related pain.

The patients' recruitment rate was lower than anticipated with about 35% of the required patients enrolled and dosed; therefore, Dr. Jean Bourgouin, the Company's new Chief Medical Officer, determined the amendments necessary in order to complete the study in a timely manner without compromising objectives and patient safety. The amended protocol will simplify the study, increase patient eligibility, lessen the burden on patients and as a result, reduce the workload required by the physicians and their clinical teams. This is expected to help accelerate patient recruitment. WEX's clinical team will meet personally with each participating centre to introduce the amended protocol and facilitate its smooth implementation. The data from the patients who have completed the study will still be evaluable and the total target enrollment will remain at up to 150 patients.

With the protocols changes the enrollment and dosing of patients in this study is expected to be completed by the end of the second quarter of 2006.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is a company dedicated to the discovery of new therapeutic agents for the treatment of moderate to severe pain, symptom relief associated with addiction withdrawal from opioid abuse, and medicines designed for local and regional anaesthesia. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the Global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China and are expanding its marketing efforts in the rest of Asia.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information

  • WEX Pharmaceuticals Inc.
    Don Evans
    Corporate Communications
    (604) 683-8880 or Toll Free: 1-800-722-7549
    WEX Pharmaceuticals Inc.
    Gordon Stanley
    Corporate Communications
    (604) 683-8880 or Toll Free: 1-800-722-7549
    (604) 683-8868 (FAX)